Biogen Inc

September 27, 2022

Alzheimer’s drug slows cognitive decline in key study

Biogen and Eisai reported the results of a large, late-stage clinical trial of lecanemab, a drug they are developing. Source link
This website uses cookies to improve your experience. By using this website you agree to our Data Protection Policy.
Read more